PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

Rhea-AI Summary

PMV Pharmaceuticals (Nasdaq: PMVP), a precision oncology company focused on p53-targeting therapies, has announced its participation in two major upcoming investor conferences. David H. Mack, Ph.D., President and CEO, and Deepika Jalota, Pharm. D., Chief Development Officer, will represent the company.

The conferences include the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 12:40 PM EST, and the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 3:10 PM EST. Management will also conduct one-on-one investor meetings during these events.

Live audio webcasts will be available online, with archived replays accessible for 90 days following each presentation through the company's Events & Presentations platform.

News Market Reaction

-2.10%

1 alert

-2.10% News Effect

On the day this news was published, PMVP declined 2.10%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings.

Oppenheimer 35^th Annual Healthcare Life Sciences Conference
Date: Wednesday, February 12, 2025
Time: 12:40 PM EST

TD Cowen 45^th Annual Health Care Conference
Date: Tuesday, March 4, 2025
Time: 3:10 PM EST

A live audio webcast of the events will be available online at Events & Presentations. An archived replay of the events will be available for 90 days following the webcast at Events & Presentations.

About PMV Pharma

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize more than four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com.

Investors Contact:
Tim Smith
Senior Vice President, Head of Corporate Development and Investor Relations
investors@pmvpharma.com

Media Contact:
Kathy Vincent
Greig Communications
kathy@greigcommunications.com

FAQ

When is PMV Pharmaceuticals (PMVP) presenting at the Oppenheimer Healthcare Conference in 2025?

PMV Pharmaceuticals will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 12:40 PM EST.

What time is PMVP's presentation at the TD Cowen Health Care Conference in March 2025?

PMVP will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 PM EST.

How long will the webcasts of PMVP's investor conference presentations be available?

The archived replays of the conference webcasts will be available for 90 days following each event.

Which executives from PMV Pharmaceuticals will participate in the 2025 investor conferences?

David H. Mack, Ph.D., President and CEO, and Deepika Jalota, Pharm. D., Chief Development Officer, will participate in the conferences.

Will PMVP management be available for individual investor meetings at the conferences?

Yes, management will participate in one-on-one investor meetings during both conferences.